Ph3 Study of Combo in therapy with low grade serous ovarian cancer (LGSOC)
Phase III Clinical Trial
A Phase 3 Randomized Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator's Choice of Treatment in Patients with Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) (VS-6766-301)
Participating Locations